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ABSTRACT
Background: Spontaneous bacterial peritonitis (SBP) is a common serious complication of liver cirrhosis 
mainly caused by bacterial translocation (BT) into ascites fluid. The most essential issue that affects BT is 
small intestinal bacterial overgrowth (SIBO), which usually caused by gastrointestinal dysmotility. This study 
was aimed to evaluate the prokinetic effects of domperidone on gastrointestinal motility and small intestinal 
bacterial overgrowth and the correlation between restoration of motility and the incidence of SIBO in patients 
with liver cirrhosis.
Method: A cross-over double blind clinical trial was conducted on patients who were treated at the ward 
and outpatient clinic from Division of Hepatology in Cipto Mangunkusumo Hospital, Jakarta and Soedarso 
Hospital, Pontianak between September 2010 and March 2011. All patients suffered from liver cirrhosis with 
ascites, gastrointestinal dysmotility and SIBO were included in the study. Out of 34 eligible patients, 16 patients 
received placebo and 18 patients received prokinetics (domperidone). Wilcoxon test was performed to analyze 
the comparison of SIBO before and after treatment in the placebo group; while paired T-test was employed for 
the prokinetics (domperidone) group. To evaluate improved balance of SIBO in the placebo and domperidone 
group, a Chi-square test was performed. 
Results: In the placebo group, 61.8% patients experienced SIBO; while in the prokinetics group, SIBO occurred 
only in 2.9% patients. Restored gastrointestinal motility took place in the prokinetics group with reduced median 
value for orocaecal transit time from 120 minutes into 90 minutes (p = 0.0001). In contrast, it went worse in the 
placebo group, i.e. from 90 minutes into 110 minutes (p = 0.002). There was a significant correlation between 
restored gastrointestinal motility and SIBO (p = 0.0001). Similarly, so does the effect of administering prokinetic 
agent on restored gastrointestinal motility (p = 0.0001) and SIBO (p = 0.0001).
Conclusion: The administration of prokinetics has been proven effective to restore gastrointestinal motility 
that may lead to reduced incidence of SIBO in patients with liver cirrhosis. 
Keywords: prokinetics, breath hydrogen test, dysmotilitas, bacterial overgrowth 
ABSTRAK
Latar belakang: Peritonitis bakteri spontan (PBS) merupakan komplikasi yang sering dan fatal pada sirosis 
hati. Penyebabnya utamanya adalah translokasi bakteri (TB) ke dalam cairan asites. Hal yang paling berperan 
dalam TB adalah adanya tumbuh lebih bakteri intestinal (TLB) yang biasanya disebabkan gangguan motilitas. 
Penelitian ini bertujuan untuk melihat pengaruh prokinetik domperidon terhadap motilitas dan TLB intestinal 
serta hubungan antara perbaikan motilitas dengan kejadian TLB pada pasien sirosis.
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Metode: Dilakukan uji klinik tersamar ganda bersilang pada pasien di bangsal rawat inap dan poliklinik 
Divisi Hepatologi Rumah Sakit Cipto Mangunkusumo, Jakarta dan Rumah Sakit Soedarso, Pontianak pada 
September 2010 hingga Maret 2011. Semua pasien penderita sirosis hati dengan asites yang mengalami gangguan 
motilitas dan TLB diikutsertakan. Dari 34 pasien yang memenuhi kriteria, sebanyak 16 pasien diberi plasebo 
dan 18 pasien diberi prokinetik (domperidon). Digunakan uji Wilcoxon untuk menganalisis perbandingan TLB 
sebelum dan sesudah perlakuan pada kelompok plasebo dan uji-T berpasangan untuk kelompok prokinetik 
domperidon. Untuk melihat perbaikan TLB pada kelompok plasebo dan domperidon digunakan uji Chi-square.
Hasil: Pada kelompok plasebo 61,8% pasien mengalami TLB, sedangkan pada kelompok prokinetik, TLB 
hanya terjadi pada 2,9% pasien. Perbaikan motilitas terjadi pada kelompok prokinetik dimana median waktu 
transit oroseikal berkurang dari 120 menit menjadi 90 menit (p = 0.0001). Sedangkan pada kelompok plasebo 
justru memburuk dari 90 menit menjadi 110 menit (p = 0,002). Terdapat hubungan bermakna antara perbaikan 
motilitas dengan TLB intestinal (p = 0,0001). Begitu pula dengan pemberian prokinetik terhadap perbaikan 
motilitas (p = 0,0001) dan TLB intestinal (p = 0,0001).
Simpulan: Pemberian prokinetik terbukti dapat memperbaiki motilitas sehingga dapat menurunkan kejadian 
TLB intestinal pada pasien sirosis hati.
Kata kunci: prokinetik, breath hydrogen test, dismotilitas, tumbuh lebih bakteri 
INTRODUCTION
Liver cirrhosis is one of hepatologic problems 
which has a relatively high morbidity and mortality. 
Among major complications of liver cirrhosis, the most 
common one is ascites. 
Liver cirrhotic patients with ascites have greater 
vulnerability for bacterial infection. Among them, 
the most common and fatal complication (25%) is 
spontaneous bacterial peritonitis (SBP).1-3 When it was 
first diagnosed in 1970, the prevalence only reached 
5-10% in patients with liver cirrhosis who also had 
ascites. In conjuction with advances in diagnostic 
approaches, several recent studies demonstrated that it 
occurs in 10-30% liver cirrhotic patients who also had 
ascites.4,5 The mortality has been reduced from 80% - 
100% in 1970’s era into 20-40% nowadays. However, 
certain condition such as renal damage that usually 
go together with SBP still has great contribution for 
high mortality rate which may be as high as 100%.2,4-6 
Moreover, there is no national data in Indonesia about 
the prevalence of liver cirrhosis; however, clinical 
data on patients with liver cirrhosis who have been 
hospitalized at internal medicine wards ranges about 
3.6 – 8.4%.7 
Some studies suggested that SBP in liver cirrhotic 
patients with ascites is a result of small intestinal 
bacterial translocation (SIBO), which has been 
transferred to extra-intestinal region, including 
into ascites fluid. As it is widely known, there is 
an existence of increased adrenergic tone in liver 
cirrhosis, which leads to reduced intestinal motility. 
The hypomotility condition causes longer intestinal 
transit time. It favors a chance for developing small 
intestinal bacterial overgrowth (SIBO). In addition, 
structural and functional damage of intestinal mucosal 
barrier against infection and suppressed immune 
system in patients with liver cirrhosis will further 
facilitate bacterial translocation and its products to 
extra-intestinal region, including into ascites fluid.1-5,8-10 
 Advances in diagnostic and therapeutic technologies 
have caused shifting paradigm of SBP from a deadly 
complication into something that can be managed 
and prevented. Various efforts have been proposed 
to complete or support treatment for SBP in order to 
have better outcomes. One of them includes improving 
gastrointestinal motility using prokinetic agents. 
Several studies recommended that administration of 
prokinetics as a supplementation of antibiotic treatment 
may reduce SBP morbidity and mortality.1,11-15 Of 
some prokinetic agents available in Indonesia, the 
relatively safe agent is domperidone. However, there 
is no empirical evidences in Indonesia, which reveal 
the effectiveness of domperidone in restoring intestinal 
motility to prevent or reduce bacterial overgrowth in 
cirrhotic patients with ascites. 
METHOD
This study was a cross-over double blinded clinical 
trial, which was conducted in 34 liver cirrhotic patients 
with ascites who visited outpatient clinic and ward 
of Hepatology Division in Cipto Mangunkusumo 
Hospital and Soedarso Hospital located in Pontianak, 
West Kalimantan between September 2010 and March 
2011. All patients with liver cirrhosis and ascites 
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aged 16 years or more (≥ 16 years) who also had 
gastrointestinal dysmotility and intestinal bacterial 
overgrowth received information about the objectives, 
advantages and risks of the study. Those patients 
were included in the study after they signed informed 
consent forms. Patients who could not sign informed 
consent form or who had other conditions that may 
affect study results were excluded from the study, 
including those with active pulmonary tuberculosis, 
disseminated intravascular coagulopathy, urinary tract 
infection, tuberculosis peritonitis, other abdominal wall 
infections, heart failure, hepatorenal syndrome, active 
bleeding and fever of more than 38oC. 
Slowed gastrointestinal motility is a gastrointestinal 
movement which is slower than normal (normal 
limit 70-90 minutes); while restored motility is an 
improved response of motility and characterized by 
faster orocaecal transit time after treatment compared 
to before treatment. Furthermore, an orocaecal transit 
time is the time needed by a substrate, lactulose, after 
being ingested until it reaches caecum. Longer or 
slower transit time is characterized by increased H2 
of or more than 10 ppm compared to the basal H2 
concentration starting from the 60 minutes during 
breath hydrogen test (BHT).
Eligible subjects who fulfilled the inclusion criteria 
were assessed with baseline screening including taking 
medical history, performing physical examination and 
laboratory tests. Data of examination and test results 
was recorded in a questionnaire form. Subjects were 
then randomly categorized into two groups. The first 
group was 16 subjects who received placebo; while 
the second group included 18 subjects who received 
prokinetics, i.e. domperidone. After 10 days, BHT 
was performed again to evaluate intestinal bacterial 
overgrowth and intestinal motility. Both groups 
received a phase of free wash-out period for 1 week. 
Subsequently, the first group received prokinetics and 
the second group received placebo for 10 days. BHT 
evaluation was repeated after the treatment had been 
completed. 
Data obtained from questionnaires was entered to 
data tables using computer program of SPSS. Data 
normality was tested using Kolmogorov Smirnov 
test. To analyze the comparison of SIBO on BHT 
between before and after treatment, Wilcoxon test 
was performed in the placebo group since the data 
was not normally distributed. While paired T-test was 
performed to analyse the comparison of SIBO on BHT 
before and after treatment in the domperidone group 
as the data was normally distributed. To evaluate 
improved SIBO in placebo and domperidone group, 
a table of 2 x 2 was used and it was further evaluated 
using Chi-square test. 
RESULTS
Of 34 subjects, there were 23 (67.6%) male 
subjects. Mean age was 53.8 ± 9.1 years. BMI of 
both groups, placebo and prokinetics groups, was not 
significantly different. Mean value of hemoglobin 
level, platelet counts, blood glucose level, prothrombin 
time, albumin level, aspartat transaminase (AST), 
alanin aminotransferase (ALT) level as well as median 
value of leukocytes count between placebo group and 
prokinetics groups were not significantly different. 
Child-Pugh class B was mostly found in both groups; 
however, there was no significant difference on criteria 
A, B, and C (Table 1).
Figure 1 shows that there was greater bacterial 
overgrowth in placebo group (61.8%) compared 
to prokinetics group (2.9%). Whereas the results 
of orocaecal transit time (OCTT) before and after 
treatment in placebo group revealed that the median 
value before treatment was 90 (90-110) minutes; while 
after treatment, the median value was 110 (90-110) 
minutes. In the prokinetics group, the median value 
before treatment was 120 (90-120) minutes, while 
after treatment the median of OCTT results was 90 
(60-120) minutes. It indicates that the OCTT in placebo 
group before and after treatment had worse results (p 
= 0.002); while in prokinetics group, there were better 
results (p = 0.0001).
A significant correlation was found between 
improved OCTT and better value of SIBO, which 
suggests that the greater OCTT improvement, the 
better value of restored SIBO (p = 0.0001) (Table 2). 
Restored SIBO and improved OCTT also showed 
significant correlation, both in placebo and prokinetics 
groups (Table 3).
DISCUSSION 
We found that there was a greater bacterial 
overgrowth in placebo group (61.8%) compared to 
prokinetics group (2.9%). Moreover, for OCTT in 
placebo group before and after treatment, there was 
worse result (p = 0.002); in contrast, in prokinetics 
group, we found better result (p = 0.0001). This 
finding is consistent with several studies revealing 
the benefits of prokinetics supplementation to restore 
gastrointestinal motility and to reduce SIBO incidence 
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Table 1. Characteristics and comparison of laboratory test results between placebo and prokinetics 
group
Variable Subjects
(n = 34)
Placebo
(n = 16)
Domperidon
(n = 18)
p
Sex
     Male
     Female
Age (years)#
     < 40 
      40-50 
      50-60
      > 60 
Education
     Elementary school
     Junior high school
     Senior high school
     College
23 (67.6%)
11 (32.4%)
53.85 ± 9.1
2 (5.9%)
12 (35.3%)
14 (41.2%)
6 (17.6%)
10 (29.4%)
12 (35.3%)
11 (32.4%)
1 (2.9%)
11 (68.8%)
5 (31.3%)
54.94 ± 9.08
0
6 (37.5%)
7 (43.8%)
3 (18.8%)
3 (18.8%)
7 (43.8%)
5 (31.3%)
1 (6.3%)
12 (66.7%)
6 (33.3%)
52.89 ± 9.34
2 (11.1%)
6 (33.3%)
7 (38.9%)
3 (16.7%)
7 (38.9%)
5 (27.8%)
6 (33.3%)
0
1.000*
0.783**
0.400*
0.738*
1.000*
1.000*
1.000
BMI (kg/m2)
Hemoglobin (g/dL)
Thrombocytes (cell/mL)
Random blood glucose level 
(mg/dL)
Albumin (g/dL)
AST (u/L)
ALT (u/L)
Prothrombin time (second)
Leukocyte (cell/mL)
Child-Pugh
     A
     B
     C
23.67 ± 2.85 23.23 ± 2.04
10.18 ± 0.99
90,937.5 ± 41,746
106 ± 16.18
2.71 ± 0.41
82.03 ± 57.2
58.37 ± 24
15.51 ± 1.45
6731.25 ± 5517.1
1 (6.3%)
8 (50%)
7 (43.8%)
24.07 ± 3.46
10.84 ± 1.73
114.666.7 ± 46.599.6
109.2 ± 15.47
2.81 ± 0.7
56.06 ± 19.73
40.87 ± 13
15.04 ± 1.57
12208.8 ± 23021.7
3 (16.7%)
9 (50%)
6 (33.3%)
0.204**
0.191**
0.13**
0.590**
0.639**
0.079**
0.110**
0.369**
0.67***
1.000*
*Chi-square test; **independent T-test; ***Mann-whitney test; #(mean, SD); BMI: body mass index; AST: aspartate transaminase; 
ALT: alanin aminotransferase
Figure 1. Bacterial overgrowth in placebo and prokinetics 
group
Figure 2. Orocaecal transit time in placebo and prokinetics group
Table 2. Correlation between improved orocaecal transit time 
and restored SIBO 
OCTT
SIBO value
p*
Restored Not restored
Improved 18 (100%) 0 (0%) 0.0001
Not improved 28 (56%) 22 (44%)
*Chi-square test; OCCT: orocaecal transit time; SIBO: small intestinal bacterial 
translocation
Table 3. Correlation of restored SIBO and motility between 
placebo and prokinetics groups 
Randomization
p*
Placebo Prokinetic
SIBO score 
Improved 13 (38.2%) 33 (97.1%) 0.0001
Not improved
OCCT
Improved
Not improved
21 (61.8%)
0 (0%)
34 (100%)
1 (2.9%)
18 (52.9%)
16 (47.1%) 0.0001
*Chi-square test; SIBO: small intestinal bacteria translocation; OCCT: orocaecal transit time
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that may prevent the development of SBP.13 Several 
experimental studies conducted by Shun-Chai Zang 
et al and Pardo et al in male rats with liver cirrhosis 
which also had bacterial overgrowth and hypomotility 
showed that prokinetics supplementation (cisapride) 
may reduce SIBO incidence and lower intestinal transit 
time. Shun-Chai Zang revealed that the incidence 
of SIBO in male rates receiving prokinetics was 
lower compared to placebo group (15% vs. 80%, p 
< 0.01). Moreover, rats that received prokinetics also 
experienced improved intestinal transit time compared 
to placebo group.16,17
In liver cirrhosis, there is increased adrenergic tone 
which results in reduced intestinal motility. Hypomotility 
condition causes longer intestinal transit time. It favors 
a chance for developing SIBO. In addition, structural 
and functional damage of intestinal mucosal barrier 
against infection and immunocompromised condition 
experienced by patients with liver cirrhosis facilitate 
bacterial translocation and its products to extra-intestinal 
region, including into ascites fluid.1-5,8-10 Gupta et al 
reported a correlation between bacterial overgrowth 
and slower orocaecal transit time, which affects SIBO 
incidence in patients with liver cirrhosis of child B 
and C criteria by 69.2%.9 Several previous studies 
have even revealed that prevention of SIBO extremely 
depends on the normality of intestinal motility.18-21 It is 
supported by some findings that there was hypomotility 
in experimental animals with cirrhosis, which also 
experienced SIBO and lower SIBO incidence in animals 
with hypomotility that treated with prokinetics agents.16,17 
Based on the pathogenesis, theoretically, improved 
intestinal transit time/OCTT will improve the incidence 
of SIBO. In this study, we found a significant correlation 
between improved OCTT and improved SIBO, which 
indicated that the greater improvement of OCTT, the 
better value of improved SIBO (p = 0.0001) (Table 
2). Such finding is consistent with the results of study 
conducted by Simadibrata, which reported a statistically 
significant correlation between gastrointestinal motility 
expressed in OCTT and the development of SIBO (p = 
0.008).22 A study conducted by Gupta et al has found a 
correlation between dysmotility and SIBO in patients 
with liver cirrhosis.9
With regard to the correlation between placebo or 
prokinetics and bacterial overgrowth as well as the 
restored motility, this study has also found significant 
results. Some other studies have also revealed similar 
results although using different materials and methods. 
For example, a study conducted by Tatsuta et al 
compared the supplementation of cisapride on placebo 
and cisapride on domperidone. The study was a cross-
over double blinded clinical trial in patients who had 
delayed gastric emptying. Obviously, in the group 
with cisapride and domperidone, they found improved 
gastric emptying time, which was statistically 
significant compared to the group receiving cisapride 
and placebo (p < 0.005).23
CONCLUSION
Prokinetics can restore intestinal motility in patients 
with liver cirrhosis who experience some disorders and 
may reduce the incidence of SIBO.
SUGGESTION
Further studies should be conducted, particularly 
comparison between restored intestinal motility 
and bacterial overgrowth in patients with liver 
cirrhosis by comparing improvement in liver 
function paramaters using more sensitive and higher 
specificity methods. 
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